Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Morie A GertzPublished in: American journal of hematology (2021)
Bortezomib, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in relapsed WM. Given WM's natural history, reduction of therapy toxicity is an important part of treatment selection.